ALPS Medical Breakthroughs
ALTAR
Score™
-5.2% info Recommen-
dation
AVOID
2019E    2020E
P/E
ratio
-17.9x P/Sales
ratio
10.9x
P/BV
ratio
5.1x Div.
yield
0.0%


  • Description
  • Performance
  • Comps
  • premium Fundamentals
  • premium Valuation
  • premium Rating
ALPS Medical Breakthroughs ETF is an exchange-traded fund incorporated in the USA. The ETF seeks investment results that correspond generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs Index (ticker symbol: PMBI).

FUND BASICS
Category US Equities
Fund Sponsor ALPS Advisors Inc
Website www.alpsetfs.com
Inception date Dec 30, 2014
Assets (mns) $207
Currency USD
Expense ratio 50 bp
Distributions Annually

FUND STRUCTURE
Regulation Open-Ended Fund
Custodian Bank of New York Mellon
Weighting Market Cap
Index replication Full
Uses derivatives No
Options available Yes

SECTOR BREAKDOWN

 


CONSTITUENT BREAKDOWN
No. of constituents 77
Wgt avg mkt cap (mns) $2,029
Large cap (>$10bn) 0.0%
Mid cap ($2-10bn) 43.6%
Small cap (<$2bn) 56.4%
Developed mkts 100.0%
Emerging mkts 0.0%

TOP TEN HOLDINGS
ALLAKOS, INC. 5.4 %
ACADIA PHARMACEUTICALS INC 5.2 %
GLOBAL BLOOD THERAPEUTICS INC 4.5 %
MORPHOSYS AG SPONSORED ADR 4.0 %
FIBROGEN INC 3.9 %
MIRATI THERAPEUTICS INC 3.8 %
UNITED THERAPEUTICS CORP 3.8 %
IMMUNOMEDICS INC 3.7 %
ALKERMES PLC 3.1 %
PTC THERAPEUTICS INC 2.7 %
Total 40.1 %

TOP COUNTRY EXPOSURE
UNITED STATES 87.7 %
GERMANY 4.0 %
IRELAND 3.1 %
NETHERLANDS 3.0 %
SWITZERLAND 0.6 %
CANADA 0.3 %
BERMUDA 0.2 %




HISTORICAL PERFORMANCE info

  Custom date range Compare to  
  thru


Standardized Annual Returns (thru November 30)
Year-to-date 1 year 5 years 10 years Since Incep.
40.5% 21.1% -- -- 10.9%

Market Correlations
versus... Beta R-squared
S&P500 1.44 45%
MSCI EAFE 1.11 22%
MSCI Emg. Mkts. 0.92 24%

Technical Indicators
Recent close $41.39
30d moving avg. $36.73
Annualized volatility 26.0%
Short interest (ETF) 0.3%
Short interest (Underlying) 10.6%
Relative strength (RSI) 79

Liquidity measures
Avg. volume (thou.) 34
Turnover 0.7%
Bid/Ask (% of price) 0.20%
ADV underlying (mns) $1,170

Distributions


FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the ALPS Medical Breakthroughs ETF based on the alternatives' overlap in portfolio holdings with SBIO. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker: SBIO Expense: 50 bp ALTAR Score™: -5.2%


ALTERNATIVE ETFs BASED ON OVERLAP WITH SBIO
Ticker Fund
Name
Overlap1
vs SBIO
(%)
Expense
ratio
(bp)
Savings
vs SBIO
(bp)
ALTAR
Score™
(%)
ALTAR
vs SBIO
(%)
BBC Virtus LifeSci Biotech Clinical Trials 37.8 79 -29 -11.1 -5.9
XBI SPDR S&P Biotech ETF 28.1 35 15 -4.4 +0.8
BTEC Principal Healthcare Innovators Index 21.0 42 8 -4.2 +1.0
IDNA iShares Genomics Immunology and Healthcare 17.7 47 3 -4.3 +0.9
FBT First Trust NYSE-ARCA Biotechnology 15.6 57 -7 -0.7 +4.4
BBP BioShares Biotech Products 14.6 79 -29 -3.7 +1.5
IBB iShares NASDAQ Biotechnology 11.8 47 3 0.4 +5.6
PTH Invesco DWA Healthcare Momentum 8.6 60 -10 -1.2 +3.9
GNOM Global X Genomics & Biotechnology 7.8 68 -18 -5.2 -0.0
CNCR Loncar Cancer Immunotherapy 6.3 79 -29 -3.4 +1.7
IWC iShares Russell Microcap 6.2 60 -10 -8.2 -3.1
PQSG PGIM QMA Strategic Alpha Small-Cap Growth 5.7 29 21 1.2 +6.3
GDNA Goldman Sachs Motif Human Evolution 5.6 50 0 1.0 +6.2
IWO iShares Russell 2000 Growth 5.5 24 26 0.8 +6.0
JKK iShares Morningstar Small Cap Growth 5.5 30 20 1.0 +6.2
IEIH iShares Evolved U.S. Innovative Healthcare 5.4 18 32 4.4 +9.5
VTWG Vanguard Russell 2000 Growth 5.4 20 30 0.9 +6.0
PSCH Invesco S&P Small Cap Health Care 4.9 29 21 2.5 +7.6
SLIM Obesity 4.4 35 15 2.2 +7.3
MFMS Motley Fool Small-Cap Growth 4.2 85 -35 -2.2 +2.9

1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

  2014 2015 2016 2017 2018 2019E 2020E
Sales per share ** ** ** ** ** ** **
Earnings per share ** ** ** ** ** ** **
Dividends per share info ** ** ** ** ** ** **
Book value per share ** ** ** ** ** ** **

 

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est. **%   Debt-to-equity **x
Asset turnover **%   Assets-to-equity **x

Return on equity

Revision activity*
*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS
  2018 2019E 2020E
Price-to-sales ** ** **
Price-to-earnings ** ** **
Price-to-cash flow ** ** **
Price-to-growth ** ** **
Price-to-book value ** ** **
Yield ** ** **

Historical valuation trends

Forward
multiple:
ALPS Medical Breakthroughs
Relative
to:
S&P500 MSCI EAFE MSCI Emg. Mkts. Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™


Calculation of ALTAR Score™
Avg. Return on Equity -34.2 %
Divided by: Fwd. P/BV 7.3 x
Less: Expense ratio 50 bp
Equals: ALTAR Score -5.2 %
info More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
COMPOSITE
RATING
1.27 CATEGORY
AVERAGE
1.56
 
The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale:

BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.

Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.
 

 

See RATING tab for calculation of ALTAR Score™
Risk & reward. Uses std. dev. as proxy for risk, ALTAR Score™ for return forecast.
Dividends paid by constituents to the fund. May differ from actual distributions to shareholders due to constituent changes, timing issues or other factors.
Monthly returns based on changes in price plus dividends. May differ from daily returns reported by funds. See below for standardized returns.